Alfa Intes

What Alfa Intes does

Alfa Intes Industria Terapeutica Splendore s.r.l. is a privately held Italian pharmaceutical company founded in 1964 and headquartered in Casoria, Italy, that develops, manufactures, and sells drugs, medical devices, and nutraceuticals exclusively for the ophthalmology sector. The company operates through three core product divisions (Farma pharmaceuticals, Dispositivi Medici medical devices, Nutraceutici nutraceuticals) and two wholly-owned subsidiaries (Chirurgia Alfa Intes for surgical products and Alfa Instruments for diagnostic instruments), giving it coverage across the ophthalmology workflow from diagnosis to post-surgical care. Its differentiated technology platform rests on liposomal formulation and hydrophilic carrier delivery systems, with two anchor assets: CurcuWIN, a curcumin formulation claiming 46x higher bioavailability than standard curcumin and used in the Diabec nutraceutical for retinal inflammatory conditions; and liposomal lactoferrin, the active in both the Kelapher 2.B periocular wound device and the Somilux ophthalmic solution. IDROFLOG, a medicated tear substitute, was recognized in the 2025 TFOS DEWS III Management and Therapy Report.

Name

Alfa Intes

Legal name

Alfa Intes Industria Terapeutica Splendore s.r.l.

Website

https://alfaintes.it

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

101–250 employees

Short description

Alfa Intes is a privately held Italian pharmaceutical company founded in 1964 that develops, manufactures, and sells ophthalmic drugs, medical devices, and nutraceuticals, serving ophthalmologists, pharmacists, and eye-care specialists across Italy and select international markets through its liposomal and hydrophilic-carrier formulation platforms.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAIACAK

Ophthalmology Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIAAAL

Ophthalmology Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAHAJAF

Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

SECONDARYHLAHAIAL

Ocular Drug Delivery Devices (Eye Droppers/Inserts)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

• Ophthalmic pharmaceuticals
• Ocular medical devices
• Ophthalmic nutraceuticals
• Liposomal ophthalmic formulations
• Eye care products

Headquarters

HQ city

Casoria

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Products (Farma): Alfa Intes manufactures and sells pharmaceutical ophthalmic products including IDROFLOG (tear substitute), Ziclor (ophthalmic gel), and prescription treatments for ocular conditions.
2. Medical Devices (Dispositivi Medici): Sale of registered medical devices including Kelapher 2.B for periocular wound and hematoma treatment, and Somilux liposomal lactoferrin ophthalmic solution.
3. Nutraceuticals (Nutraceutici): Sale of nutraceutical products including Diabec (curcumin-based) for retinal inflammatory conditions, and related dietary supplements targeting eye health.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Alfa Intes manufactures and sells ophthalmic pharmaceutical products, registered medical devices, and nutraceuticals for the treatment of ocular conditions including dry eye, ocular infections, periocular wounds and hematomas, and retinal inflammatory diseases. The portfolio includes Idroflog (medicated tear substitute), Ziclor (ophthalmic gel), Somilux (liposomal lactoferrin solution), Diabec (curcumin-based nutraceutical), and Kelapher 2.B (liposomal lactoferrin ointment), supported by subsidiaries Chirurgia Alfa Intes (surgical products) and Alfa Instruments (diagnostic instruments).

Product overview

Alfa Intes is an ophthalmic pharmaceutical company organized into three main product categories: Farmaci (pharmaceutical drugs), Dispositivi Medici (medical devices), and Nutraceutici (nutraceuticals). The portfolio includes prescription and over-the-counter ophthalmic products for various eye conditions. Key products include Idroflog (innovative tear substitute), Ziclor (ophthalmic gel for infections/inflammation), Somilux (lactoferrin-based ophthalmic solution), Diabec® (curcumin-based nutraceutical for retinal conditions), and Kelapher 2.B (liposomal lactoferrin ointment for periocular wounds). The company also operates related sites for surgical and diagnostic ophthalmic products.

Differentiator

Problem solved

Functional benefit

Brands

• Alfa Academy: Eye Health Education Hub - an educational project dedicated to ophthalmologists and healthcare professionals in the ophthalmological sector, offering specialized scientific training through webinars, live surgeries, and updated scientific materials.
• Chirurgia Alfa Intes
• Alfa Instruments

Quantifiable outcome

• Diabec (curcumin + standard therapy) achieved significant improvement in Best Corrected Visual Acuity (BCVA) at 6 and 12 months in uveitis patients with macular edema, with significant reduction in central macular thickness (CMT), compared to standard therapy alone.
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• SIFI S.p.A. SIFI is an Italian specialty ophthalmic pharma company developing drugs, medical devices, and nutraceuticals for eye care. Highly comparable to Alfa Intes in geography (Italy), therapeutic focus (anterior and posterior segment), and product mix spanning pharmaceuticals, devices, and supplements.
• Sooft Italia S.p.A. Sooft Italia is an Italian ophthalmic pharma focused on ocular surface, dry eye, and nutritional supplements for eye health, overlapping directly with Idroflog, Ziclor, and Diabec categories in Alfa Intes' portfolio.
• Visufarma S.p.A. Visufarma is an Italian ophthalmic pharma with a portfolio of prescription drugs, medical devices, and nutraceuticals for dry eye, retinal, and ocular surface conditions, competing head-to-head with Alfa Intes in Italian ophthalmology channels.
• Théa Pharma: Théa is a European specialty ophthalmology company offering branded ocular pharmaceuticals, dry-eye products, and surgical devices, making it a comparable mid-size specialty pharma peer in ophthalmology.
• Farmigea S.p.A. Farmigea is an Italian ophthalmic pharma producing prescription eye drops, tear substitutes, and ocular surface products, with comparable therapeutic categories to Idroflog and Ziclor.

Broad incumbents

• Dompé Farmaceutici S.p.A. Dompé is a larger Italian biopharma with a meaningful ophthalmology franchise (e.g., cenegermin for neurotrophic keratitis) plus broader pharma operations, providing a relevant comparison point as a larger Italian player with overlapping eye-care interests.
• Bausch + Lomb (Bausch Health): Bausch + Lomb is a global ophthalmology incumbent offering branded pharmaceuticals, surgical devices, and consumer vision care; it competes broadly with Alfa Intes in dry eye, ocular inflammation, and surgical ophthalmology.
• Alcon Inc. Alcon is a global leader in eye care across surgical, vision care, and ophthalmic pharmaceuticals; comparable as the dominant broad incumbent in the same therapeutic categories Alfa Intes targets.
• Allergan / AbbVie (ophthalmology): AbbVie's ophthalmology franchise (formerly Allergan) competes in retinal disease, dry eye (Restasis), and ocular inflammation — directly relevant comparables in the indications where Alfa Intes positions Diabec, Ziclor, and Idroflog.
• Nidek Co., Ltd. Nidek is a global ophthalmic device and equipment manufacturer, comparable to Alfa Instruments (Alfa Intes' diagnostic instruments subsidiary) in serving ophthalmology clinics with diagnostic and surgical ophthalmic equipment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alfa Intes